Skip to main content

Hassan Shaikh

Associate

[email protected]

+1.202.434.7375

Share:

Hassan’s practice focuses on advising a broad range of clients—including health plans, pharmacy benefit managers, rebate aggregators, providers, and private equity firms—in contract negotiations, complex industry transactions, and compliance and regulatory matters. He regularly counsels plans, PBMs, rebate aggregators, and providers on regulatory, operational and contracting matters; and often advises clients on compliance with the anti-kickback statute and corporate practice of medicine prohibitions.

Hassan leverages his prior experience  representing private equity firms in various acquisitions, restructurings, and growth equity transactions to provide reasoned and pragmatic solutions to a wide range of client needs. 

Prior to joining Mintz, Hassan was an associate with a large, international law firm in New York City, and then later, with a boutique law firm in Los Angeles.

Hassan received his J.D. from Duke Law School, where he was an editor of the Duke Journal of Constitutional Law and Public Policy. He received his B.S.Ed and MPH from Baylor University, with a concentration in health education.

viewpoints

Bridgette Keller speaks with the Mintz Health Law team about what they are grateful for as they look back on a year of client service, mentorship, and working together as a team.
Read more
Though the flurry of state PBM-focused legislation slowed down with the summer recess, there has still been plenty of noteworthy PBM news. This roundup focuses on state Medicaid enforcement activities involving Centene and provides a brief overview of recent legislative activity.
Read more
MintzRx is a regular newsletter providing you with everything you need to know to stay abreast of the legal, regulatory, and industry developments across the pharmaceutical supply chain.
Read more
2022 continues to see a surge in state-led PBM enforcement efforts. This roundup provides a brief summary of Louisiana’s complaint against United Healthcare and OptumRx related to its Medicaid program and recent state legislative actions.
Read more

PBMs Continue to Draw Federal Scrutiny: PBM Transparency Act of 2022

June 30, 2022 | Blog | By Bridgette Keller, Hassan Shaikh, Sergey Smirnov, Jewel Duberry-Douglas

As we noted in our last PBM Regulatory Roundup, there has been a wave of state regulation focused on PBM practices in the wake of Rutledge and Webhi. However, PBMs are also facing federal reform efforts. The Pharmacy Benefit Manager (PBM) Transparency Act of 2022 (the Act) was recently proposed in the U.S. Senate and intends to incentivize “fair and transparent” PBM practices, prohibit spread pricing and claw backs of payments to pharmacies, and empower the Federal Trade Commission (FTC) and state attorneys general in enforcement actions to stop “unfair and deceptive” PBM business practices.

At the same time, government watchdogs are also taking action: on June 7, 2022, the FTC announced that it would launch an inquiry into vertically integrated PBMs, and the Office of the Inspector General (OIG) for the Department of Health and Human Services expects to release a report in 2022 following completion of its analysis of Medicaid Managed Care Organization (MCO) PBM pricing.
Read more
The latest episode of Mintz’s Health Law Diagnosed podcast covers key takeaways from our 6th Annual Pharmacy & Pharmaceutical Industry Summit.
Read more
As states move forward with their 2022 legislative sessions in earnest, we have been examining whether the Wehbi decision has had any initial effects on PBM-focused legislation. This roundup provides a brief recap of the significance of Wehbi, summarizes the Eighth Circuit’s opinion and holding, and highlights some state measures that have been proposed or passed during the flurry of PBM-focused legislation we have already seen in 2022.
Read more
The next post in our series analyzing the recently proposed Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs rule (Proposed Rule), focuses on a regulation impacting Part D sponsors and their reporting of pharmacy price concessions. According to CMS, the proposed change—which would require the “negotiated price” of a covered Plan D drug to be the lowest possible payment made to a pharmacy by a Plan D sponsor—is expected to (i) reduce out-of-pocket costs for plan beneficiaries at the pharmacy counter, (ii) create greater drug price transparency, (iii) stabilize the operating environment for pharmacies and (iv) improve market competition.
Read more
In this episode of the Health Law Diagnosed podcast, members of the Mintz Health Law team discuss their health law–focused 2022 New Year’s resolutions and how they’re helping clients and colleagues navigate the continued challenges and opportunities of the current era.
Read more
Read less

News & Press

News Thumbnail
Theresa Carnegie, Lauren Moldawer, and Hassan Shaikh co-authored an article published by Law360 on the Inflation Reduction Act's Medicare drug pricing negotiation program.
News Thumbnail
In a recent installment of Law360 Pulse’s “Ask a Mentor” column, Managing Member of Mintz’s Washington, D.C. Office and Chair of the firm’s Health Law, Communications, Antitrust & ML Strategies Division Susan Berson, who regularly mentors firm attorneys, and Associate Hassan Shaikh, who transitioned from a private equity mergers and acquisitions practice to a health care regulatory role, offered retooling tips to associates.
Read less

Publications

  • Co-author, Assessing College Students' Use of Campus Recreation Facilities Through Individual and Environmental Factors, Recreational Sports Journal, (October 2018)
Read less

Involvement

  • Member, American Bar Association
  • Member, American Health Law Association
  • Member, Health Care Compliance Association
Read less